Advertisement
Screener

RELMADA THERAPEUTICS, INC. (RLMD) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other

2.9 / 5 stars · 23/40 Roast Me

RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other

RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other of 1.02 million shares for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-12.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther · last filed 2020-08-12

  • RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, other for the quarter ending 2020-06-30 was -136.72K shares.
  • RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, other for the quarter ending 2020-03-31 was 1.16M shares.
  • RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, other for the quarter ending 2019-09-30 was 279.63K shares.
  • RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, other for the quarter ending 2016-03-31 was -29.50K shares.
  • RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, other for fiscal 2017 was 4.11M shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Other 12 month
2020-06-30-136.72K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12
1.02M shares
10-Q · filed 2020-08-12
2020-03-311.16M shares
10-Q · filed 2020-05-15
2019-09-30279.63K shares
10-Q · filed 2019-11-13
2017-06-304.11M shares
10-K · filed 2017-09-28
2017-01-312.50M shares
10-K · filed 2017-09-28
2016-03-31-29.50K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-09
-81.03K shares
derived: sum of 2 quarters · filed 2016-05-09
683.60K shares
10-Q · filed 2016-05-09
2015-12-31-51.53K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-05
713.10K shares
10-Q · filed 2016-02-05
2015-09-30764.62K shares
10-Q · filed 2015-11-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Rezolute, Inc. (RZLT)United States$0.382B-6.45
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63